A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
GA Depot
Recommended Posts
- Over 70% of MS patients in rehab take 5 or more medications, study finds
- New research project to explore how women with MS experience menopause
- MS progression is unpredictable, but I’m learning to adapt
- Lucid-MS moves toward clinical trial in US that will enroll MS patients
- With MS, movement can be one of the greatest teachers